Cancer drug could ease rare nerve disorder
NCT ID NCT07392229
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether zanubrutinib, a drug used for certain blood cancers, can improve nerve function in people with anti-MAG neuropathy—a rare condition causing numbness, weakness, and balance problems. About 50 adults in Italy will take the drug for 12 months. Researchers will check if symptoms get better using standard nerve tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Zanubrutinib (a targeted cancer drug that blocks a protein called BTK)
What this could lead to
If successful, this could offer a new treatment option for a rare nerve disease that currently has few effective therapies.
What could go wrong
This is an early-phase trial with only 50 participants and no placebo group, so results may not be definitive. The drug also carries risks like infection and bleeding.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTI-MAG IGM-ASSOCIATED DEMYELINATING POLYNEUROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CTU Ematologia, Grande Ospedale Metropolitano Niguarda
RECRUITINGMilan, Milan, 20162, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
SC UCO Ematologia, Ospedale Maggiore di Trieste
RECRUITINGTrieste, Trieste, 34129, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UOC Ematologia, Azienda Ospedale Università Padova
RECRUITINGPadova, PD, 35128, Italy
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••